Patents by Inventor Richard H. Scheuermann

Richard H. Scheuermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210325369
    Abstract: Biomarkers and uses thereof, as well as methods for using same for identifying vaccine recipients who will respond to a single dose of vaccine. In addition, an integration model for identifying biomarkers is also provided, such that the biomarkers form a network of signatures associated with a vaccine responder.
    Type: Application
    Filed: July 29, 2019
    Publication date: October 21, 2021
    Inventors: Wayne C. Koff, Richard H. Scheuermann, Tobias Kollmann, Casey P. Shannon, Scott J. Tebbutt
  • Publication number: 20170190786
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: August 11, 2016
    Publication date: July 6, 2017
    Inventors: Brian M. Fendly, Gail Dianne Phillips, Richard H. Scheuermann, Jonathan W. Uhr
  • Publication number: 20150252113
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death-via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: October 10, 2014
    Publication date: September 10, 2015
    Inventors: Brian M. FENDLY, Gail Dianne PHILLIPS, Richard H. SCHEUERMANN, Jonathan W. UHR
  • Publication number: 20110033460
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Application
    Filed: October 22, 2010
    Publication date: February 10, 2011
    Inventors: Brian M. Fendly, Gail Dianne Phillips, Richard H. Scheuermann, Jonathan W. Uhr
  • Patent number: 5686072
    Abstract: The anti-tumor activity of a mixture of anti-CD22 and anti-CD19 immunotoxins is shown to be significantly enhanced in SCID/Daudi mice with disseminated human Daudi lymphoma. Unexpectedly identical enhancement was observed employing a combination of the anti-CD22 immunotoxin with unconjugated anti-CD19 antibodies. Thus combinations of an anti-CD22 immunotoxin and an anti-CD19 immunotoxin or antibody act synergistically and provide advantageous compositions and methods for immunotherapeutic treatment of various diseases including cancer and autoimmune disorders. Also disclosed is data indicating that certain anti-CD19 antibodies alone inhibit proliferation of CD19-positive cells by inducing cell cycle arrest.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: November 11, 1997
    Assignee: Board of Regents, The University of Texas
    Inventors: Jonathan W. Uhr, Ellen S. Vitetta, Richard H. Scheuermann
  • Patent number: 5612185
    Abstract: Disclosed are methods for the identification and characterization of tumor cell types present within malignant populations, and novel methods of cancer treatment. Tumor cells in cell cycle arrest have been identified, purified and characterized according to their size, altered morphology, surface phenotype and expression of oncogenes. Tumor cell cycle arrest can be induced in mice lacking an immune system solely upon administration of anti-idiotype antibodies. Methods of manipulating specific signals from the cell surface to alter the malignant phenotype of transformed cells are disclosed, as are methods for either eliminating or specifically maintaining tumor cells in cell cycle arrest.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: March 18, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan W. Uhr, Ellen S. Vitetta, Louis J. Picker, Richard H. Scheuermann